References
- Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis 2002;34(Suppl 1):S4–16
- Hooper DC. Mode of action of fluoroquinolones. Drugs 1999;58(Suppl 2):6–10
- Abbott RL, Asbell PA, Sahm DF. Ocular TRUST: a new tool for ophthalmology. Ophthalmology Times 2007 July 1:1–4
- Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in aqueous fluid and corneal tissue after topical ophthalmic administration in human volunteers before penetrating keratoplasty. Invest Ophthalmol Vis Sci 2003;44:E-Abstract 4272
- Kowalski RP, Yates KA, Romanowski EG, et al. An ophthalmologist’s guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology 2005;112:1987
- Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoro quinolones. Ophthalmology 2000;107:1497–502
- Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999;106: 1313–18
- Yeh DL, Stinnett SS, Afshari NA. Analysis of bacterial cultures in infectious keratitis, 1997 to 2004. Am J Ophthalmol 2006;142: 1066–8
- Callegan MC, Ramirez R, Kane ST, et al. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther 2003;20: 246–52
- NDA 21–199, Microbiology Review. Washington, DC: FDA/ Center for Drug Evaluation and Research, 2000. Available at: http://www.fda.gov/cder/foi/nda/2000/21–199_quixin_microbr.pdf [Last accessed 4 September 2007]
- Fiscella RG, Nguyen TK, Cwik MJ, et al. Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology 1999;106:2286–90
- Garcia-Saenz MC, Arias-Puente A, Fresnadillo-Martinez MJ, et al. Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin. Journal of cataract and refractive surgery 2001;27:1969–74
- Pea F, Ferrari E, Pavan F, et al. Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery. Antimicrob Agents Chemo 2005;49:2554–7
- Puustjarvi T, Terasvirta M, Nurmenniemi P, et al. Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. Graefes Arch Clin Exp Ophthalmol 2006;244:1633–7
- Sakamoto H, Sakamoto M, Hata Y, et al. Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur J Ophthalmol 2007;17:372–6
- Kim DH, Stark WJ, O’Brien TP, et al. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 2005;112: 1992–6
- Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;112: 466–9
- Fukuda M, Inoue A, Sasaki K, et al. The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. Jpn J Ophthalmol 2004;48:93–6
- Donnenfeld ED, Schrier A, Perry HD, et al. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. Ophthalmology 1994;101:902–5
- Behrens-Baumann W. Absorption of topically administered ciprofloxacin, ofloxacin and gentamicin in the inflamed rabbit eye. Ophthalmologica 1996;210:119–22